President & CEO
Stephen Benoit brings to MDI Therapeutics broad experience in VC-backed start-ups and small and large-cap public companies in the pharmaceuticals, food & agriculture biotechnology, food safety training and education, consumer packaged foods, and specialty ingredients industries. Prior to joining MDI Therapeutics, Mr. Benoit was CEO of Metabolic Solutions Development Company (MSDC), a clinical-stage developer of small molecule therapeutics to treat diseases associated with metabolic dysfunction. During Mr. Benoit's tenure, MSDC raised more than $70 million from top-tier and regional VC's, family offices, angels, and high net worth individuals, including a recent $40 million financing for a new spinout company (Cirius Therapeutics) developing MSDC's Phase 2b program for the treatment of NASH, which was led by Frazier Healthcare Partners, Novo Ventures. In addition, the company successfully completed three Phase 2 clinical trials (diabetes, Alzheimer's) and several collaborations with academic researchers (NASH, PKD, Parkinson's), and made significant advances in a small molecule drug discovery program (metabolic diseases). Mr. Benoit continues to serve on the MSDC Board of Managers, and is a consultant to Cirius Therapeutics.
Prior to MSDC, Mr. Benoit was the Founding President & COO of the International Food Protection Training Institute, and a co-founder, President & CEO of NanoMed Pharmaceuticals, a developer of nanoparticle-formulated therapeutic agents to treat cancer. Previously, he held senior management positions with a developer of direct-to-consumer personal genetic assessments, a Fortune 250 global food manufacturing company, a small-cap public company that developed and manufactured antimicrobial peptides for food and animal health products, and a small-cap public company that pioneered food & agricultural biotechnology. He began his career at Bank of America.
Mr. Benoit earned a Masters of Business Administration, Finance and a Bachelor of Business Administration, Finance from Loyola Marymount University (Los Angeles). He has been a Visiting Executive Lecturer at the University of Virginia, Darden School of Business, (Post-Merger Integrations) and Western Michigan University (Functional Foods).
|Daniel A. Lawrence
Founder/Chairman of the Scientific Advisory Board
Daniel A. Lawrence is the Frederick G. L. Huetwell Professor of Basic Research in Cardiovascular Medicine at the University of Michigan, and a recognized world leader in serpin biology. He has published over 120 peer-reviewed articles, holds numerous patents in the field, and was awarded the prestigious 2010 International Society for Fibrinolysis and Proteolysis Prize. He has served as the Chair of the Plasminogen Activation & Extracellular Proteolysis Gordon Conference, and Co-Chair of the Xth International Workshop on Molecular & Cellular Biology of Plasminogen Activation.Professor Lawrence’s scientific career has focused on the impact of serpins in the pathology of vascular function and disease, where he has made significant discoveries. Dr. Lawrence was a member of the team that cloned and purified plasminogen activator inhibitor-1 (PAI-1), allowing its recognition as a member of the serpin family of structurally related proteins that inactivated proteases via a then unknown mechanism. He proceeded to study the serpin mechanism of action, and was the first to propose protease inhibition through distortion of the protease catalytic site by the transfer of free energy trapped in the serpin structure. Dr. Lawrence has pioneered research in advancing an understanding of how the unique molecular structure of serpins contributes to diseases as diverse as inflammation, fibrosis, and thrombosis, including being the first to identify a novel serpin target site that could potentially be exploited to pharmacologically regulate a variety of family members and functions. View Dr. Lawrence's full publication list